Aims: Patients with end-stage renal disease (ESRD) and atrial fibrillation present a challenge for thromboembolic prevention, given their elevated risks of both thromboembolism and bleeding. Anticoagulants carry a higher bleeding risk in this population without clear evidence of thromboembolic benefit. This study aims to define the role of left atrial appendage occlusion (LAAO) as a preventive strategy for patients with ESRD. Methods and results: A systematic literature review was conducted to identify studies reporting outcomes in patients with ESRD who underwent LAAO. Meta-analyses of aggregate and individual patient data were performed to evaluate acute and long-term outcomes and compare them with those of patients without ESRD. Seventeen studies reporting data from 24 127 patients, including 1047 with ESRD, were included. Procedural complications were more common in patients with ESRD (RR 2.23; P = 0.02), with a pooled rate of 4% (95% CI, 1–9%). There was no significant difference in thromboembolic event rates during follow-up between the groups (IRR 1.44; P = 0.16), but major bleeding incidence was higher among patients with ESRD (IRR 1.84; P < 0.01). Individual patient-level data from seven studies comprising 4745 patients (268 with ESRD) were obtained and analysed. Similarly, there was no significant association between ESRD and stroke/TIA incidence (HR, 1.22; 95% CI, 0.66–2.26), but major bleeding was higher on patients with ESRD (HR, 1.65; 95% CI, 1.01–2.69). Conclusion: LAAO represents a feasible option for thromboembolic prevention in patients with ESRD, although these patients have an increased risk of complications and bleeding.
1 December 2025 in Circulation: Arrhythmia and Electrophysiology
BACKGROUND: Cavotricuspid isthmus (CTI) ablation is frequently performed either as a standalone procedure or in combination with pulmonary vein isolation. With the rapid adoption of pulsed field ablation for atrial fibrillation, it is essential to delineate the utility of this modality in treating CTI-dependent atrial flutter (AFL). This study aims to evaluate the procedural and clinical outcomes of CTI ablation using pulsed field energy. METHODS: We conducted a retrospective analysis of consecutive patients who underwent pulsed field ablation for CTI-dependent AFL between January 2024 and March 2025. The primary end points were acute procedural success, periprocedural complications, and CTI-dependent AFL recurrence during follow-up. RESULTS: A total of 132 patients underwent CTI nonthermal ablation. The median age was 69.5 years, and 27.3% were female. The Farawave catheter was used in 93.9% of cases, PulseSelect in 4.5%, and Sphere-9 in 1.5%. Acute block was achieved in 99.2% of patients, although 8 required adjunctive radiofrequency ablation to complete the line. Periprocedural complications included transient ST-segment elevation in 2 patients and transient conduction disturbances in 3. During a median follow-up of 114 days (n=131), 5 patients (3.8%) experienced recurrence of typical AFL. The 6-month typical AFL-free survival estimate was 93.6%. CONCLUSIONS: Pulsed field ablation appears to be a feasible and effective strategy for CTI-dependent AFL. However, anatomic variability may limit its universal applicability with current catheter designs. Although acute procedural success is high, the long-term durability of the CTI block and its comparative efficacy versus conventional thermal ablation remain areas requiring further investigation.
Pulmonary vein isolation (PVI) has demonstrated acceptable success rates; however, there is still potential for improvement. Pulmonary reconnection remains the main problem and the role of adjunctive strategies, such as repeat mapping to guide additional lesions to enhance durability of pulmonary vein isolation, remains uncertain. This study aimed to evaluate the impact of post-PVI high-density remapping with guided incremental lesions on long-term recurrence-free survival. This study included consecutive patients who underwent PVI between 2015 and 2023. Patients were divided into 2 groups based on whether they received post-PVI high-density remapping. Those in the remapping group with documented areas of incomplete ablation received incremental lesions to achieve complete ablation. The primary endpoint was recurrence-free survival. A total of 588 patients, with a mean follow-up of 25.8 months, were included. Post-PVI remapping was performed in 243 patients, while 345 patients underwent conventional PVI. Post-PVI remapping with guided incremental lesions improved recurrence-free survival compared with conventional PVI (adjusted hazard ratio 0.75, 95% confidence interval [CI] 0.57-0.99, P = .04). This benefit was especially notable in patients with paroxysmal atrial fibrillation (hazard ratio 0.69, 95% CI 0.49-0.96, P = .027). Complication rates and procedure times were comparable between the 2 groups. For patients undergoing their first radiofrequency ablation, 1-year success was higher in those who underwent PVI remapping (adjusted odds ratio 1.70, 95% CI 1.04–2.77, P = .03). However, long-term outcomes were comparable between the 2 groups. Postablation mapping effectively identifies and addresses proarrhythmic foci, potentially reducing atrial fibrillation recurrence and improving patient outcomes.